LQDA Quote, Financials, Valuation and Earnings

Establishment Labs Holdings, Inc. has a net margin of 15.82% compared to Liquidia Corp.'s net margin of -4.05%. Liquidia Corp.'s return on equity of -163.27% beat Establishment Labs Holdings, Inc.'s return on equity of -165.45%.

Liquidia Corp. has a consensus price target of $49.89, signalling upside risk potential of 36.09%. On the other hand Establishment Labs Holdings, Inc. has an analysts' consensus of $89.00 which suggests that it could grow by 40.49%. Given that Establishment Labs Holdings, Inc. has higher upside potential than Liquidia Corp., analysts believe Establishment Labs Holdings, Inc. is more attractive than Liquidia Corp..

Liquidia Corp. has a beta of 0.525, which suggesting that the stock is 47.464% less volatile than S&P 500. In comparison Establishment Labs Holdings, Inc. has a beta of 0.914, suggesting its less volatile than the S&P 500 by 8.575%.

Liquidia Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Establishment Labs Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Liquidia Corp. pays -- of its earnings as a dividend. Establishment Labs Holdings, Inc. pays out -- of its earnings as a dividend.

Liquidia Corp. quarterly revenues are $92M, which are larger than Establishment Labs Holdings, Inc. quarterly revenues of $64.6M. Liquidia Corp.'s net income of $14.6M is higher than Establishment Labs Holdings, Inc.'s net income of -$2.6M. Notably, Liquidia Corp.'s price-to-earnings ratio is -- while Establishment Labs Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Liquidia Corp. is 20.67x versus 8.84x for Establishment Labs Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Kura Oncology, Inc. has a net margin of 15.82% compared to Liquidia Corp.'s net margin of -467.23%. Liquidia Corp.'s return on equity of -163.27% beat Kura Oncology, Inc.'s return on equity of -92.88%.

Liquidia Corp. has a consensus price target of $49.89, signalling upside risk potential of 36.09%. On the other hand Kura Oncology, Inc. has an analysts' consensus of $32.27 which suggests that it could grow by 273.1%. Given that Kura Oncology, Inc. has higher upside potential than Liquidia Corp., analysts believe Kura Oncology, Inc. is more attractive than Liquidia Corp..

Liquidia Corp. has a beta of 0.525, which suggesting that the stock is 47.464% less volatile than S&P 500. In comparison Kura Oncology, Inc. has a beta of 0.224, suggesting its less volatile than the S&P 500 by 77.626%.

Liquidia Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kura Oncology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Liquidia Corp. pays -- of its earnings as a dividend. Kura Oncology, Inc. pays out -- of its earnings as a dividend.

Liquidia Corp. quarterly revenues are $92M, which are larger than Kura Oncology, Inc. quarterly revenues of $17.3M. Liquidia Corp.'s net income of $14.6M is higher than Kura Oncology, Inc.'s net income of -$81M. Notably, Liquidia Corp.'s price-to-earnings ratio is -- while Kura Oncology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Liquidia Corp. is 20.67x versus 11.24x for Kura Oncology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Lexicon Pharmaceuticals, Inc. has a net margin of 15.82% compared to Liquidia Corp.'s net margin of -282.72%. Liquidia Corp.'s return on equity of -163.27% beat Lexicon Pharmaceuticals, Inc.'s return on equity of -40.2%.

Liquidia Corp. has a consensus price target of $49.89, signalling upside risk potential of 36.09%. On the other hand Lexicon Pharmaceuticals, Inc. has an analysts' consensus of $3.36 which suggests that it could grow by 98.82%. Given that Lexicon Pharmaceuticals, Inc. has higher upside potential than Liquidia Corp., analysts believe Lexicon Pharmaceuticals, Inc. is more attractive than Liquidia Corp..

Liquidia Corp. has a beta of 0.525, which suggesting that the stock is 47.464% less volatile than S&P 500. In comparison Lexicon Pharmaceuticals, Inc. has a beta of 0.943, suggesting its less volatile than the S&P 500 by 5.737%.

Liquidia Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexicon Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Liquidia Corp. pays -- of its earnings as a dividend. Lexicon Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Liquidia Corp. quarterly revenues are $92M, which are larger than Lexicon Pharmaceuticals, Inc. quarterly revenues of $5.5M. Liquidia Corp.'s net income of $14.6M is higher than Lexicon Pharmaceuticals, Inc.'s net income of -$15.5M. Notably, Liquidia Corp.'s price-to-earnings ratio is -- while Lexicon Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Liquidia Corp. is 20.67x versus 12.32x for Lexicon Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Viemed Healthcare, Inc. has a net margin of 15.82% compared to Liquidia Corp.'s net margin of 7.63%. Liquidia Corp.'s return on equity of -163.27% beat Viemed Healthcare, Inc.'s return on equity of 11.13%.

Liquidia Corp. has a consensus price target of $49.89, signalling upside risk potential of 36.09%. On the other hand Viemed Healthcare, Inc. has an analysts' consensus of $13.00 which suggests that it could grow by 41.3%. Given that Viemed Healthcare, Inc. has higher upside potential than Liquidia Corp., analysts believe Viemed Healthcare, Inc. is more attractive than Liquidia Corp..

Liquidia Corp. has a beta of 0.525, which suggesting that the stock is 47.464% less volatile than S&P 500. In comparison Viemed Healthcare, Inc. has a beta of 1.232, suggesting its more volatile than the S&P 500 by 23.227%.

Liquidia Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viemed Healthcare, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Liquidia Corp. pays -- of its earnings as a dividend. Viemed Healthcare, Inc. pays out -- of its earnings as a dividend.

Liquidia Corp. quarterly revenues are $92M, which are larger than Viemed Healthcare, Inc. quarterly revenues of $76.2M. Liquidia Corp.'s net income of $14.6M is higher than Viemed Healthcare, Inc.'s net income of $5.8M. Notably, Liquidia Corp.'s price-to-earnings ratio is -- while Viemed Healthcare, Inc.'s PE ratio is 24.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Liquidia Corp. is 20.67x versus 1.37x for Viemed Healthcare, Inc.. Usually stocks with elevated PS ratios are considered overvalued.